GENDICINE GENE THERAPY:
THE WORLD'S FIRST APPROVED CANCER GENE THERAPY
Gendicine gene therapy is a targeted cancer treatment using recombinant human p53 gene delivery to restore tumor suppression and support cancer control.
analyticsAt a Glance
- check_circleWorld's first government-approved cancer gene therapy โ approved in China in 2003
- check_circleDelivers functional p53 tumour suppressor gene via adenoviral vector
- check_circleMost evidence in head and neck squamous cell carcinoma
- check_circleAvailable at selected centres in China; often combined with chemotherapy or radiation
What Is Gendicine, and Why Does It Matter?
Gendicine (recombinant human adenovirus-p53) is a gene therapy medicine produced by Shenzhen SiBiono GeneTech, approved by China's SFDA in 2003 for head and neck squamous cell carcinoma โ making it the world's first commercially approved cancer gene therapy. It is relevant for solid tumour patients for three reasons: it has a validated 20-year clinical history in China, it targets the most universally disrupted pathway in solid cancers (p53/TP53), and it is most used as an add-on to radiation or chemotherapy โ not as a replacement.
โGendicine marked the world's first real-world transition of cancer gene therapy from experimental concept to approved commercial oncology product.โ
World's First Approved Cancer Gene Therapy
Approved by China's State FDA in October 2003 for HNSCC โ two decades before Western regulatory bodies approved any cancer gene therapy product. Over 20 years of commercial use across Chinese oncology centres.
The p53 / TP53 Connection
p53 is the genome's primary guardian โ controlling cell division, initiating apoptosis in damaged cells, and suppressing tumour growth. TP53 mutations or deletions occur in >50% of all human solid tumours. Gendicine directly addresses this by reintroducing a functional p53 gene.
Combination Therapy โ Not Monotherapy
Gendicine's primary clinical value is additive: it sensitises tumour cells to radiation and chemotherapy by restoring the apoptotic pathways those treatments rely on. It is rarely used โ or expected to work effectively โ as a standalone agent.
China Access โ International Patients
Outside China, Gendicine is only available through clinical trials. CancerFax has an established network of Chinese oncology centres with direct Gendicine experience โ coordinating eligibility review, hospital matching, travel logistics, and post-treatment follow-up.
How Gendicine Works: Step-by-Step Mechanism
Gendicine uses a replication-defective adenovirus as a vehicle to deliver the wild-type p53 gene directly into tumour cells โ restoring tumour suppressor function that mutations have disabled.
- 1
Intratumoral Delivery
Gendicine is delivered directly into tumour tissue via intratumoral injection. Intracavitary or intravascular routes are used depending on tumour location and the treating centre's protocol.
- 2
Adenoviral Vector Enters Tumour Cells
The genetically engineered, replication-defective adenovirus enters cancer cells. Because it is replication-defective, it cannot reproduce or spread โ it acts purely as a delivery vehicle for the therapeutic gene.
- 3
Wild-Type p53 Gene Expression Restored
Once inside the tumour cell, the vector releases the functional wild-type p53 gene. Tumour cells that previously could not express p53 โ due to TP53 mutation or deletion โ begin producing functional p53 protein.
- 4
Cell Cycle Arrest & Apoptosis
Restored p53 signalling causes cell cycle arrest, pushes tumour cells towards programmed cell death (apoptosis), and suppresses further tumour growth โ reactivating the biological brakes that TP53 mutations had removed.
- 5
Enhanced Sensitivity to Radiation & Chemotherapy
Gendicine-treated tumours demonstrate improved sensitivity to concurrently or subsequently administered radiotherapy and chemotherapy. Restored apoptotic pathways amplify the cell-killing effects of both modalities.
Gendicine: Key Facts
- 2003Year of China's SFDA ApprovalFirst cancer gene therapy approved anywhere in the world โ 20+ years of real-world commercial use across Chinese centres.
- >50%Solid Tumours with TP53 Mutation or DeletionThe biological target Gendicine addresses โ making it broadly relevant across solid tumour oncology.
- 4Documented Combination StrategiesRadiation, chemotherapy, surgery/ablation, and emerging immunotherapy combinations โ each with published clinical rationale.
- 20+Years of Published Clinical ReviewsSummaries describing thousands of patients treated in China across heterogeneous tumour types and combination regimens.
Which Solid Tumours Are Most Relevant?
Evidence strength for Gendicine is NOT equal across all tumour types. Patients should understand this distinction clearly before exploring the therapy.
Head & Neck Squamous Cell Carcinoma (HNSCC) โ Strongest Evidence
This is Gendicine's approved indication. The original 2003 SFDA approval was for HNSCC in combination with radiotherapy. Two decades of clinical use, the most consistent published data, and the greatest institutional experience in Chinese centres all sit here. For patients with locoregional HNSCC pursuing radiation-based treatment, this is the most evidence-supported setting.
Lung Cancer
Published clinical reviews describe use of Gendicine in non-small cell lung cancer in combination with chemotherapy or local ablation. TP53 mutations are common in NSCLC. Evidence is weaker than for HNSCC; tumour accessibility for intratumoral delivery varies by lesion location.
Liver Cancer (HCC)
Hepatocellular carcinoma reports describe intratumoral and intravascular Gendicine administration, often combined with TACE or ablation. Tumour accessibility via image-guided delivery is generally feasible. TP53 pathway disruption is frequent in HCC.
Ovarian Cancer
Intracavitary (intraperitoneal) administration has been explored in ovarian cancer, leveraging the peritoneal route for locoregional delivery. Published reviews describe use as part of multi-agent combination protocols.
Other Solid Tumours
Colorectal cancer, osteosarcoma, and several other solid tumour types appear in published clinical summaries spanning two decades. Evidence is heterogeneous โ varying tumour types, dosing regimens, and combination approaches make generalisation difficult. Individual case assessment is essential.
How Gendicine Fits Into a Treatment Plan
Gendicine is rarely used as standalone therapy. Its clinical value lies in combination โ making cancer cells more susceptible to treatments already being administered.
Gendicine + Radiotherapy
The most well-documented and evidence-supported combination โ particularly in HNSCC. Restored p53 signalling reduces radiation resistance by reactivating apoptotic pathways that radiation depends on. This is the combination underpinning the original 2003 approval.
Gendicine + Chemotherapy
Restoring p53-mediated apoptosis reactivates the same cell death pathways that chemotherapy agents exploit. Published clinical experiences describe improved chemosensitivity in tumours treated with Gendicine concurrently or sequentially with systemic agents.
Gendicine + Surgery or Local Ablation
Pre- or post-operative use to reduce recurrence risk or improve tumour margin control is being explored. Combination with TACE, RFA, or cryoablation has been described โ particularly in liver cancer โ to enhance local control from ablative procedures.
Gendicine + Immunotherapy (Emerging)
Restoring p53 signalling may modulate the tumour microenvironment โ reducing immunosuppressive signals and allowing more immune effector cells to infiltrate the tumour. Combination with checkpoint inhibitors is an active area of scientific interest and early clinical investigation.
Who May โ and May Not โ Be Considered for Gendicine
Patient selection is highly individualised. Eligibility is determined through careful review of clinical, pathological, and logistical factors by an experienced oncology team.
May Be Considered
- Confirmed solid tumour โ locoregional diseaseMost relevant for patients with locally advanced or locoregional disease rather than widespread systemic metastases.
- Recurrent or residual tumour after prior treatmentPatients with residual or recurrent disease after standard first-line therapy who are exploring additional options.
- Planning combination with radiation or chemotherapyGendicine adds most value as an adjunct to standard local or systemic therapy, not as a standalone agent.
- Accessible tumour for intratumoral deliveryFeasibility of intratumoral, intracavitary, or intravascular delivery depends on tumour location and anatomical access.
- Adequate organ function and performance statusReasonable ECOG/Karnofsky score and organ reserves to tolerate Gendicine alongside combination treatment.
May NOT Be Ideal Candidates
- Poor performance status or limited functional reservePatients unable to tolerate the combination regimen that makes Gendicine most effective.
- Uncontrolled active infection or severe immune conditionsAdenoviral vector delivery requires adequate immune management capacity at the treating centre.
- Severe hepatic or renal dysfunctionAffects tolerance to Gendicine itself and concurrent chemotherapy agents.
- Rapidly progressive systemic diseaseRequires urgent systemic control; Gendicine's local mechanism does not address rapidly disseminating disease.
- No safe delivery route to tumourWhere anatomical location makes intratumoral, intracavitary, or intravascular delivery technically infeasible.
Tests Required Before Considering Gendicine
A complete clinical picture is required before eligibility assessment. The treating team needs current imaging, pathology, blood work, and a full treatment history.
| Test Category | Specific Tests | Purpose |
|---|---|---|
| Pathology & Molecular | Histopathology report; IHC panel relevant to tumour type; TP53 status (if available) | Confirms tumour type, subtype, grade; Gendicine is not biomarker-gated but TP53 status informs expected benefit |
| Imaging | PET-CT, contrast CT, or MRI within last 4โ6 weeks; bone scan if skeletal metastases a concern | Current disease extent; tumour accessibility for intratumoral delivery; response baseline |
| Full Blood Count | CBC with differential, platelet count | Baseline haematological function; infection risk; treatment tolerance |
| Liver Function | LFTs, AST, ALT, bilirubin, albumin, total protein | Tolerance to Gendicine and concurrent chemotherapy; critical if HCC or liver metastases present |
| Renal Function | Serum creatinine, eGFR, urea | Drug clearance and combination chemotherapy tolerance |
| Coagulation | PT, APTT, INR | Required if intratumoral injection is planned โ bleeding risk assessment |
| Treatment History | Prior surgeries, chemotherapy lines, radiation fields/doses, targeted agents, current medications | Determines combination regimen selection and remaining treatment options |
| Performance Status | ECOG / Karnofsky scale assessment | Determines fitness for combination regimen; key eligibility factor |
Gendicine vs CAR-T vs TIL Therapy: Key Differences
These three therapies are frequently discussed together as 'advanced cancer treatments' โ but they are biologically distinct with very different indications, mechanisms, and access pathways.
| Feature | Gendicine | CAR-T Cell Therapy | TIL Therapy |
|---|---|---|---|
| Mechanism | Delivers p53 gene into tumour cells via adenoviral vector | Genetically engineers patient's T-cells to express synthetic CAR receptor | Expands tumour-infiltrating T-cells billions-fold and reinfuses |
| Genetic Engineering | Of the viral vector โ not the patient's cells | Yes โ patient's T-cells are permanently modified | No โ T-cells are expanded but unmodified |
| Best Cancer Type | Solid tumours (HNSCC primary; lung, liver, ovarian) | Blood cancers (B-ALL, DLBCL, Multiple Myeloma) | Solid tumours (melanoma FDA-approved; cervical, NSCLC in trials) |
| Administration | Intratumoral, intracavitary, or intravascular injection | IV infusion after leukapheresis and 3โ6 wk manufacturing | IV infusion after tumour biopsy and 3โ6 wk manufacturing |
| Manufacturing | Off-the-shelf โ no patient-specific manufacturing | Patient-specific โ 3โ6 weeks per patient | Patient-specific โ 3โ6 weeks from biopsy |
| Regulatory Status | SFDA-approved (China) since 2003 | 9 FDA-approved products (US/EU); NMPA-approved products (China) | FDA-approved (lifileucel/Amtagvi) for melanoma, 2024 |
| Typical Use | Combination with radiation or chemotherapy | After lymphodepletion; with IL-2 support in some protocols | After lymphodepletion; with high-dose IL-2 post-infusion |
| Cost Complexity | Lower โ off-the-shelf product; centre costs vary | High โ $400Kโ$500K in US; lower in China | High โ ~$200Kโ$400K; lower through Chinese trial access |
Side Effects and Safety Profile
Gendicine's safety profile is consistently described in published literature as relatively mild compared to systemic chemotherapy โ particularly at the Gendicine-specific level. Side effects from concurrent therapies must be considered separately.
Transient Fever
The most commonly reported Gendicine-specific adverse effect. Typically mild to moderate and self-limiting โ usually resolving within 24โ48 hours. Related to the immune response triggered by the adenoviral vector.
Injection-Site Reactions
Localised swelling, pain, or discomfort around the tumour delivery site. Severity depends on tumour location, anatomical accessibility, and the volume and number of injections administered.
Flu-Like Symptoms
Fatigue, chills, and myalgia in the 24โ48 hours after injection โ typical of the immune response to an adenoviral vector. Generally self-resolving with supportive care.
Concurrent Therapy Toxicity
The safety profile experienced by any patient is a combination of Gendicine-related effects AND the concurrent radiation or chemotherapy regimen. Patients and families must weigh combined toxicity. All treatment decisions require proper informed consent and baseline assessment.
Realistic Outcome Expectations
CancerFax prioritises honest, evidence-based information. Here is what the published evidence supports โ and what it does not.
What Published Reviews Consistently Describe
Restoration of wild-type p53 tumour suppressor signalling in tumour tissue. Improved tumour response rates when combined with radiotherapy in HNSCC and other settings. Enhanced chemosensitivity across multiple solid tumour types. A 20-year commercial safety and efficacy record in China with a well-characterised mild side-effect profile.
What Gendicine Is Not
It is not a cure for all solid tumours. It is not expected to work as standalone monotherapy in most cases. It is not appropriate for every patient โ individual assessment is mandatory. It should not be pursued without access to a centre with documented Gendicine experience. Literature spans heterogeneous populations and regimens โ generalising outcomes to individual cases requires caution.
Outcome Determinants
Individual outcomes depend on: disease stage and tumour burden, tumour biology and TP53 pathway status, prior treatment history and remaining treatment options, the combination regimen selected alongside Gendicine, and the experience of the treating centre with this specific protocol.
Explore Gene Therapy Guides & Resources
In-depth guides on Gendicine, gene therapy, and related advanced cancer treatments.
- What Is Gene Therapy for Cancer?
- How Gene Therapy Works
- Types of Gene Therapy in Oncology
- Viral Vectors in Gene Therapy
- Eligibility for Gene Therapy
- Tests Before Gene Therapy
- Gene Therapy Treatment Process
- Side Effects of Gene Therapy
- Success Rates of Gene Therapy
- Gene Therapy vs CAR-T Therapy
- Clinical Trials in Gene Therapy
- Cost of Gene Therapy Worldwide
- Gendicine for Head and Neck Cancer
- Gendicine for Lung Cancer
- Gendicine for Liver Cancer
- p53 Tumour Suppressor: Why It Matters in Cancer
- Gene Therapy for Solid Tumors
- Gene Therapy for Cancer Patients
- How to Access Cancer Treatment in China
- Questions to Ask Before Starting Gene Therapy
Frequently Asked Questions
The most common questions from patients and families exploring Gendicine gene therapy.
Understanding Gendicine
What is Gendicine?
Gendicine is the world's first gene therapy approved for the treatment of cancer, developed by Shenzhen SiBiono GeneTech and approved in China in 2003. It was approved in 2003 by the China Food and Drug Administration as a first-in-class gene therapy product to treat head and neck cancer and entered the commercial market in 2004.
The therapy works by delivering a healthy copy of the p53 gene directly into tumor cells using a modified, harmless virus as a carrier. The wild-type p53 protein expressed by Gendicine-transduced cells is a tumor suppressor that is activated by cellular stress and mediates cell-cycle arrest and DNA repair or induces apoptosis, senescence, and autophagy, depending upon cellular stress conditions.
Why does Gendicine target the p53 gene specifically?
The p53 gene is one of the body's most important tumor suppressors, often described as the genome's guardian because it controls whether a damaged cell repairs itself or self-destructs. In many cancers, this gene is either mutated or lost, allowing damaged cells to continue growing unchecked. Gendicine works by adding a functioning copy of this gene directly into tumor cells, restoring a key braking mechanism that the cancer had lost. Activated wild-type p53 exhibits a strong bystander effect, thereby activating apoptosis in surrounding cells without being physically present there, which means its effect can extend beyond just the cells that directly receive the gene therapy.
Eligibility & Safety
How effective is Gendicine?
Gendicine has one of the largest real-world treatment histories of any gene therapy. Based on 12 years of commercial use in more than 30,000 patients and more than 30 published clinical studies, Gendicine has exhibited an exemplary safety record, and when combined with chemotherapy and radiotherapy, it has demonstrated significantly higher response rates than for standard therapies alone. In the original head and neck cancer trials that led to approval, after eight weeks of a joint treatment of radiotherapy and weekly gene therapy injections, 64% of late-stage tumors experienced complete regression and 32% experienced partial regression. It has also shown benefit beyond head and neck cancer. In liver cancer, Ad-p53 combined with TACE showed significant advantages in terms of clinical efficacy, survival rate, and safety compared to TACE alone and effectively improved patient quality of life and immune function.
Can Gendicine cure cancer?
Gendicine is not used as a stand-alone cure and is almost always given alongside standard treatments like chemotherapy and radiotherapy, where it appears to improve their effect rather than replace them. The clinical literature backs this combination approach specifically. Thirteen published studies that include long-term survival data showed that Gendicine combination regimens yield progression-free survival times that are significantly longer than standard therapies alone.
One important nuance is that Gendicine's benefit does not appear limited to patients with a specific p53 mutation status. Although the p53 gene is mutated in more than 50% of all human cancers, p53 mutation status did not significantly influence efficacy outcomes and long-term survival rate for Ad-p53-treated patients. Even so, it should be understood as a treatment that strengthens the effect of standard therapy, not one that replaces the need for it.
Treatment & Safety
What does Gendicine treatment involve?
Gendicine is given as a direct injection into the tumor, most commonly alongside a course of radiotherapy or chemotherapy. In the head and neck cancer protocol that led to its approval, patients received eight weeks of joint treatment with radiotherapy and weekly gene therapy injections. For liver cancer, it is often delivered through the same artery used for TACE, allowing the gene therapy and the chemoembolization to be combined in one regional treatment. The exact schedule and number of injections depend on the tumor type, location, and the treatment plan set by the oncology team.
What are the side effects of Gendicine?
Gendicine has an unusually clean safety record for a cancer therapy, largely because the adenoviral carrier used to deliver the gene does not replicate or cause illness on its own. Across more than a decade of use, the most consistently reported side effect has been mild and short-lived. No serious adverse events have been reported, except for vector-associated transient fever, which occurred in 50 to 60% of patients and persisted for only a few hours. This safety profile was noted from the earliest clinical experience, with the company's chief executive stating at the time that the only side effect of Gendicine was self-limited fever. This mild profile is one reason it has been combined so widely with other, more intensive treatments.
Access and availability
Is Gendicine available outside China?
Gendicine is approved and commercially available in China but has not received approval from international regulators such as the FDA or EMA, so it is not available as a standard treatment outside China. One p53-based therapeutic, Gendicine, is currently approved for commercial use in China, and it remains, more than two decades later, primarily accessible through Chinese hospitals and cancer centers with experience administering it. Patients interested in Gendicine generally need to travel to China and be evaluated at a center familiar with its use, particularly in combination with radiotherapy, chemotherapy, or TACE, depending on the cancer type.
How can CancerFax help patients access Gendicine?
CancerFax helps patients and families understand if Gendicine is a relevant option for their cancer type and, when appropriate, connects them with experienced Chinese hospitals that have long experience administering it, especially for head and neck cancer, lung cancer, and liver cancer in combination with TACE.
This support can include reviewing the diagnosis, tumor type, and prior treatment history, arranging expert second opinions, and coordinating the practical side of accessing treatment in China, including hospital communication, documentation, translation, visa support, and travel arrangements. Because Gendicine is almost always used in combination with other treatments and its suitability depends on cancer type and stage, the first step is always a careful case review by the treating oncology team.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Exploring Gendicine Gene Therapy for Your Solid Tumour?
Upload your medical reports and our oncology navigation team will assess your eligibility, connect you with experienced Chinese oncology centres, and walk you through your options โ honestly, and with no pressure.
This content is for informational purposes only and does not constitute medical advice. Gendicine is approved in China; its approval status varies by jurisdiction. Always consult a qualified oncologist before making treatment decisions.